Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia

Cytokine

Volumn 56, Issue 3, 2011, Pages 842-849

  Stefanutti, Claudia ^a   Morozzi, Claudia ^a   Petta, Andrea ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Kaneka Pharma Europe NV   (Belgium)

Author keywords

Atherosclerosis; Cytokines; Inflammation; LDL apheresis; Lipid apheresis

Indexed keywords

CYTOKINE; LIPID; LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ACUTE PHASE RESPONSE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CYTOKINE RESPONSE; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPOPROTEINEMIA; PLASMAPHERESIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

BLOOD COMPONENT REMOVAL; CYTOKINES; DYSLIPIDEMIAS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL;

EID: 81455141336     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.027     Document Type: Review

References (84)

1. Tedgui A., Mallat Z. Cytokines in atherosclerosis:pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
2. Ait-Outfella H., Taleb S., Mallat Z., Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011, 31:969-979.
3. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q. Is atherosclerosis an immunologically mediated disease?. Immunol Today 1995, 16:27-33.
4. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
5. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
6. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993, 11:767-804.
7. Zhang H., Wu L.M., Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm 2011, 2011:949072.
8. Li H., Freeman M.W., Libby P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 1995, 95:122-133.
9. Filonzi E.L., Zoellner H., Stanton H., Hamilton J.A. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor production in human arterial smooth muscle. Atherosclerosis 1993, 99:241-248.
10. González F., Rote N.S., Minium J., Weaver A.L., Kirwan J.P. Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine 2010, 51(3):240-244.
11. Libby P., Sukhova G., Lee R.T., Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25(2):9-12.
12. Thompson G.R., Catapano A., Sahebc S., Atassi-Dumont M., Barbir M., Eriksson M., et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. J Clin Lipidol 2010, 4:346-349.
13. Hemphill L.C. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010, 4:346-349.
14. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. McGraw-Hill; 2001. pp. 2753-2787.
15. Koschinsky M, Marcovina SM. Lipoprotein(a). In: Ballantyne C, editor. Clinical lipidology: a companion to Braunwauld's heart disease. Philadelphia: Saunders Elsevier; 2009. pp. 130-143.
16. Tziomalos K., Athyros V.G., Wierzbicki A.S., Mikhailidis D.P. Lipoprotein a: where are we now?. Curr Opin Cardiol 2009, 24:351-357.
17. Gonbert S., Malinsky S., Sposito A.C., Laouenan H., Doucet C., Chapman M.J., et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 164:305-311.
18. Crouse J.R. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996, 7:321-326.
19. Sirtori C.R., Calabresi L., Ferrara S., Pazzucconi F., Bondioli A., Baldassarre D., et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000, 10:247-251.
20. Shewmon D.A., Stock J.L., Rosen C.J., Heiniluoma K.M., Hogue M.M., Morrison A., et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994, 14:1586-1593.
21. Gonbert S., Malinsky S., Sposito A.C., Laouenan H., Doucet C., Chapman M.J., et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 48:1454-1459.
22. Akaike M., Azuma H., Kagawa A., Matsumoto K., Hayashi I., Tamura K., et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48:1454-1459.
23. Suk D.J., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008, 52:124-131.
24. Plenge J.K., Hernandez T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106(12):1447-1452.
25. Dujovne C.A., Harris W.S., Altman R., Overhiser R.W., Black D.M. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000, 85:350-353.
26. Cobbaert C., Jukema J.W., Zwinderman A.H., Withagen A.J., Lindemans J., Bruschke A.V. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 1997, 30:1491-1499.
27. Duriez P., Dallongeville J., Fruchart J.C. Lipoprotein(a) as a marker for coronary heart disease. Br J Clin Pract 1996, 77A:54-61.
28. Nordestgaard B.G., ChapmanMJ Ray.K., Borén J., Andreotti F., Watts G.F., Ginsberg H., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
29. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., et al. Group of clinical investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009, 6(3):229-239.
30. Stefanutti C., D'Alessandri G., Russi G., De Silvestro G., Zenti M.G., Marson P., et al. Reatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atherosclerosis Suppl 2009, 10:89-94.
31. Maher V.M., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.Q., Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771-1774.
32. Stefanutti C., Di Giacomo S., Vivenzio A. Comparison between different techniques of LDL-apheresis. Int J Art Organs 1997, 21:66-71.
33. Moriarty P. LDL-apheresis therapy: current therapeutic practice and potential future use. Future Lipidol 2006, 1(3):299-308.
34. Kobayashi S., Moriya H., Maesato K., Okamoto K., Ohtake T. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 2005, 20(4):239-243.
35. Thompson G.R. HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255.
36. Knisel W., Di Nicuolo A., Pfohl M., Muller H., Risler T., Eggstein M., et al. Different effects of two methods of low density lipoprotein apheresis on the coagulation and fibrinolitic systems. J Int Med 1993, 234:479-487.
37. Giansante C., Bordin P., Fiotti N., Calabrese S., Petrucco A., Da Col P.G., et al. Activation of coagulation by LDL-apheresis device. Blood Coagul Fibrinolysis 1996, 7:447-452.
38. Julius U., Siegert G., Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int Artif Organs 2000, 3:199-206.
39. Dihazi H., Koziolek M.J., Sollner T., Kahler E., Klingel R., Neuhoff R., et al. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 2008, 23:2925-2935.
40. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
41. Mabuchi H., Koizumi J., Shimizu M., et al. Long term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercolesterolemia. Am J Cardiol 1998, 82:1489-1495.
42. Gordon B.R. Incorporation of low density lipoprotein apheresis into the treatment program of patients with severe hypercolesterolemia. Curr Atherosclerosis Rep 2000, 2:308-313.
43. Cattin L., Petrucco A., Cazzolato G., Bittolo Bon G., Borelli V., Nardon E., et al. Low density lipoprotein-apheresis decreases oxidized low density lipoprotein and monocyte to endothelial cells. ASAIO J 1997, 43:209-213.
44. Stefanutti C., Di Giacomo S., Vivenzio A., Isacchi G.C., Masella R., Caprari P., et al. Acute and long term effects of low density lipoprotein (LDL) apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clin Sci 2000, 100(2):191-198.
45. Empen K., Otto C., Brödl U.C., Parhofer K.G. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apher 2002, 17:38-43.
46. Bláha M., Krejsek J., Bláha V., Andrýs J., Vokurková D., Malý J., et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res 2004, 53(3):273-278.
47. Wang Y., Walli A.K., Überfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
48. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004, 116:9-16.
49. Gibson C.A., Shih J., Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 2001, 158:495-498.
50. Nakamura T., Kawagoe Y., Ogawa H., Ueda Y., Hara M., Shimada N., et al. Effect of low density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis 2005, 45:48-53. (Previous # 46).
51. Prowse C. Biocompatibility and the non-infectious serious hazards of transfusion. Blood Transf 2003, 2:102-109.
52. Wojciak-Stothard B., Entwistle A., Garg R., Ridley A.J. Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 1998, 176:150-165.
53. Edens H.A., Parkos C.A. Modulation of epithelial and endothelial paracellular permeability by leukocytes. Adv Drug Deliv Rev 2000, 41:315-328.
54. Libby P., Okamoto Y., Rocha V.Z., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74(2):213-220.
55. Rovers C., Netea M.G., de Bont N., Demacker P.N.M., Jacobs C., Kullberg B.J., et al. LPS-induced cytokine production and expression of b2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998, 141:99-105.
56. Suzuki M., Yamane S., Matsugane T., Nobuto T., Azuma N., Nishide T., et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs 1996, 20(4):296-302.
57. Sampietro T., Tuoni M., Ferdeghini M., Ciardi A., Marraccini P., Prontera C., et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997, 96:1381-1385.
58. Kojima S., Shida M., Tanaka K., Takano H., Yokoyama H., Kuramochi M. Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis. Ther Apher 2001, 5(1):2-6.
59. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003, 7(4):431-434.
60. Nakamura T., Kawagoe Y., Matsuda T., Takahashi Y., Sekizuka K., Ebihara I., et al. Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. Kidney Blood Press Res 2003, 26(3):185-191.
61. Utsumi K., Kawabe M., Hirama A., Ueda K., Kamada Y., Arii K., et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2007, 377(1-2):198-200.
62. Otto C., Berster J., Otto B., Parhofer K.G. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J Clin Apher 2007, 22(6):301-305.
63. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 2009, 24(6):247-253.
64. Stefanutti C., Vivenzio A., Di Giacomo S., Ferraro P.M. Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis. Cytokine 2011, 55(2):245-250.
65. Boos K.S., Trautwein A., Seidel D., Morsch G. Endotoxin removal in septicaemia using the HELP-system: first in vitro results. Artif Organs 1995, 10:1041.
66. Samtleben W., Bengsch S., Boos K.S., Seidel D. HELP apheresis in the treatment of sepsis. Artif Organs 1998, 22:43-46.
67. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
68. Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 2005, 23(6):494-500.
69. Thompson G.R., Lowenthal R., Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975, 1:1208-1211.
70. Naoumovaa R.P., Thompsonb G.R., Soutar A.K. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004, 15(4):413-422.
71. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercolesterolemia. Hokuriku-FH LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
72. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., et al. LDL-apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835.
73. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y., et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid lowering therapy in patients with familial hypercholesterolemia: a multicenter study. The LAARS Investigators. Atherosclerosis 1992, 95:1-13.
74. Darbon J.M., Tournier J.F., Tauber J.P., Bayard F. Possible role of protein phosphorylation in the mitogenic effect of high density lipoproteins on cultured vascular endothelial cells. J Biol Chem 1986, 261:8002-8008.
75. Norata G.D., Catapano A.L. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manage 2005, 1:119-129.
76. Shah P.K., Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001, 104:2376-2383.
77. Young C.E., Karas R.H., Kuvin J.T. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev 2004, 12:107-119.
78. Nofer J.R., Fobker M., Höbbel G., et al. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysophingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 2000, 39:15199-15207.
79. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., Fernández J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999, 103:219-227.
80. Epand R.M., Stafford A., Leon B., et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994, 14:1775-1783.
81. Sugatani J., Miwa M., Komiyama Y., Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 1996, 13:73-88.
82. Rizvi A.A. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 2009, 338(4):310-318.
83. Mackay C.R. Moving target: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008, 9:988-998.
84. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95(1):76-82.